SCHEMBL4404729

SCHEMBL4404729

CC(=O)N[C@@H](Cc1cccc(CCc2cccc(C[C@@H](NC(C)=O)C(=O)O)c2)c1)C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.51
FOLH1 Q04609 1/20 0.51
GNPAT O15228 1/20 0.50
CTSS P25774 1/20 0.50
CTSK P43235 1/20 0.50
HDAC3 O15379 1/20 0.50
HDAC4 P56524 1/20 0.50
HDAC1 Q13547 1/20 0.50
HDAC7 Q8WUI4 1/20 0.50
HDAC2 Q92769 1/20 0.50
HDAC10 Q969S8 1/20 0.50
HDAC11 Q96DB2 1/20 0.50
HDAC8 Q9BY41 1/20 0.50
HDAC6 Q9UBN7 1/20 0.50
HDAC9 Q9UKV0 1/20 0.50
HDAC5 Q9UQL6 1/20 0.50
PAM P19021 1/20 0.50
LMNA P02545 1/20 0.50
TACR1 P25103 1/20 0.49
MME P08473 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13811865 1.00 L3MBTL1 (0.51) L3MBTL1FOLH1GNPATCTSSCTSK
SCHEMBL3002363 0.86 NOS2 (0.55) L3MBTL1FOLH1GNPATCTSSCTSK
SCHEMBL3002357 0.86 NOS2 (0.55) L3MBTL1FOLH1GNPATCTSSCTSK
SCHEMBL9828630 0.86 TACR1 (0.58) L3MBTL1FOLH1GNPATCTSSCTSK
Afalanine SCHEMBL331330 0.85 CTSS (0.65) L3MBTL1GNPATCTSSCTSKPAM
Afalanine SCHEMBL158612 0.85 CTSS (0.65) L3MBTL1GNPATCTSSCTSKPAM
Afalanine SCHEMBL8587729 0.85 CTSS (0.65) L3MBTL1GNPATCTSSCTSKPAM
Afalanine SCHEMBL158613 0.85 CTSS (0.65) L3MBTL1GNPATCTSSCTSKPAM
SCHEMBL21037199 0.85 SLC1A1 (0.54) L3MBTL1FOLH1GNPATCTSSCTSK
SCHEMBL6774455 0.85 GNPAT (0.51) L3MBTL1FOLH1GNPATCTSSCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7553809-B2 Fc receptor modulators and uses thereof ILEXUS PTY LIMITED (AU) 2009-06-30 US disclosed
US-20060057144-A1 Fc receptor modulators and uses thereof ILEXUS PTY LIMITED (AU) 2006-03-16 US disclosed
US-6835753-B2 Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt ILEXUS PTY LIMITED (AU) 2004-12-28 US disclosed
US-20020061844-A1 Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt ILEXUS PTY LIMITED 2002-05-23 US disclosed
US-6355683-B1 ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE ILEXUS PTY LIMITED (AU) 2002-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020061844-A1 Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt FCGR2A, FCGR1A, FCER2 L3MBTL1 4804/4885FOLH1 600/4885GNPAT 1590/4885
US-20060057144-A1 Fc receptor modulators and uses thereof FCGR1A, FCER2, FCGR2A L3MBTL1 4588/4885FOLH1 1072/4885GNPAT 2612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.